NI201700154A - Moduladores alostéricos positivos de - Google Patents
Moduladores alostéricos positivos deInfo
- Publication number
- NI201700154A NI201700154A NI201700154A NI201700154A NI201700154A NI 201700154 A NI201700154 A NI 201700154A NI 201700154 A NI201700154 A NI 201700154A NI 201700154 A NI201700154 A NI 201700154A NI 201700154 A NI201700154 A NI 201700154A
- Authority
- NI
- Nicaragua
- Prior art keywords
- treat
- positive allosteric
- allosteric modulators
- prevent
- diseases
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000007205 Muscarinic M2 Receptor Human genes 0.000 abstract 1
- 108010008407 Muscarinic M2 Receptor Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se refiere a moduladores alostéricos positivos del receptor de M2 muscarínico, especialmente a l - arilnaftiridina - 3 - carboxamidas 7 sustituidas novedosas, a los procesos de preparación de los mismos, al uso de los mismos, por sí solos o en combinaciones para tratar y/o prevenir enfermedades y al uso de las mismos para producir medicamentos para tratar y/o prevenir enfermedades, en particular para tratar y/o prevenir trastornos cardiovasculares y/o trastornos renales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15171127 | 2015-06-09 | ||
| EP16156676 | 2016-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201700154A true NI201700154A (es) | 2018-10-19 |
Family
ID=56101466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201700154A NI201700154A (es) | 2015-06-09 | 2017-12-07 | Moduladores alostéricos positivos de |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10435403B2 (es) |
| EP (2) | EP3307741B1 (es) |
| JP (1) | JP6908536B2 (es) |
| KR (1) | KR20180016485A (es) |
| CN (1) | CN107949562B (es) |
| AU (1) | AU2016274433B2 (es) |
| BR (1) | BR112017026561A2 (es) |
| CA (1) | CA2988468A1 (es) |
| CL (1) | CL2017003124A1 (es) |
| CO (1) | CO2017012622A2 (es) |
| CR (1) | CR20170566A (es) |
| CU (1) | CU20170158A7 (es) |
| DO (1) | DOP2017000288A (es) |
| EA (1) | EA035465B1 (es) |
| EC (1) | ECSP17081322A (es) |
| HK (1) | HK1254348A1 (es) |
| IL (2) | IL256119A (es) |
| MX (1) | MX370113B (es) |
| NI (1) | NI201700154A (es) |
| PE (1) | PE20180252A1 (es) |
| PH (1) | PH12017502224A1 (es) |
| SG (1) | SG11201710164QA (es) |
| TN (1) | TN2017000498A1 (es) |
| TW (1) | TW201716405A (es) |
| UY (1) | UY36714A (es) |
| WO (1) | WO2016198342A1 (es) |
| ZA (1) | ZA201800125B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018014868A (es) | 2016-06-02 | 2019-09-13 | Cloudbreak Therapeutics Llc | Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma. |
| WO2018011017A1 (de) | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| CN110215899B (zh) * | 2019-04-01 | 2022-03-25 | 重庆科技学院 | 一种氨基酸功能化的金属有机骨架材料及其制备方法和应用 |
| CN114340618A (zh) * | 2019-09-10 | 2022-04-12 | 克劳德布雷克医疗有限责任公司 | 减轻与翼状胬肉相关的对眼外观的担忧的方法 |
| CN111057045A (zh) * | 2019-12-18 | 2020-04-24 | 安徽红杉生物医药科技有限公司 | Hcv ns3/4a蛋白酶抑制剂中间体及其合成方法、应用 |
| CN114105881B (zh) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
| CN113072480B (zh) * | 2021-04-13 | 2022-09-30 | 常州佳德医药科技有限公司 | 一种手性(-)-5-氮杂螺[2.4]庚烷-7-醇、制备方法及应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3906365A1 (de) | 1988-07-15 | 1990-01-18 | Bayer Ag | 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe |
| IT1239283B (it) * | 1989-11-08 | 1993-10-19 | Erba Carlo Spa | Uso di un agente muscarinico da solo o insieme ad un noto farmaco antiaritmico per la prevenzione e/o il trattamento dell'aritmia ventricolare. |
| CA2168764C (en) | 1993-08-13 | 2000-01-18 | Sung June Yoon | Novel quinolone carboxylic acid derivatives |
| US6964966B2 (en) | 2001-04-25 | 2005-11-15 | Wockhardt Limited | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| WO2003050107A1 (en) | 2001-12-13 | 2003-06-19 | Wockhardt Limited | New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| CN1168446C (zh) * | 2002-08-26 | 2004-09-29 | 夏国瑾 | 氢溴酸槟榔碱作为制备抗心律失常药物的应用 |
| WO2004112763A2 (en) * | 2003-05-21 | 2004-12-29 | Board Of Regents, The University Of Texas System | Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure |
| JP2005012561A (ja) | 2003-06-19 | 2005-01-13 | Sony Corp | 画像処理装置、画像処理方法および画像投射装置 |
| EP1650192A4 (en) * | 2003-07-24 | 2007-03-21 | Astellas Pharma Inc | QUINOLONE DERIVATIVE OR SALT THEREOF |
| WO2005026165A1 (en) | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| WO2005026145A2 (en) | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| DE10343098A1 (de) * | 2003-09-18 | 2005-04-14 | Bayer Healthcare Ag | Tetrahydrochinoxaline und ihre Verwendung |
| WO2005049602A1 (en) | 2003-11-18 | 2005-06-02 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| JP2007513955A (ja) | 2003-12-09 | 2007-05-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナフチリジン誘導体およびそれらのムスカリン受容体の調節剤としての使用 |
| JP5000493B2 (ja) * | 2004-05-20 | 2012-08-15 | ディアメディカ インコーポレイテッド | インスリン抵抗性を治療するための製薬組成物、同製薬組成物の調製においてベタネコール及びｎ−アセチルシステインを使用する方法及び同製薬組成物を含むキット |
| AR057555A1 (es) * | 2005-10-27 | 2007-12-05 | Merck Frosst Canada Ltd | Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo |
| CN101411705B (zh) * | 2007-10-17 | 2011-06-01 | 北京赛德维康医药研究院 | 用于防治动脉粥样硬化的药物组合物 |
| WO2010093341A1 (en) | 2009-02-10 | 2010-08-19 | Janssen Pharmaceutica N.V. | C-7 isoxazolinyl quinolone/naphthyridine derivatives useful as antibacterial agents |
| SI2512243T1 (sl) | 2009-12-17 | 2016-07-29 | Merck Sharp & Dohme Corp. | Pozitivni alosterični modulatorji receptorja kinolin amid m1 |
| US20130289019A1 (en) * | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| CN103183676B (zh) * | 2013-03-12 | 2015-04-08 | 中国医学科学院医药生物技术研究所 | 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用 |
| GB201409044D0 (en) | 2014-05-21 | 2014-07-02 | Ucl Business Plc | New compounds |
| AU2015342017B2 (en) | 2014-11-03 | 2020-02-06 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
| CR20170594A (es) | 2015-06-09 | 2018-04-27 | Abbvie Inc | Moduladores de receptor nuclear |
| CN107849040B (zh) | 2015-06-09 | 2021-04-06 | 肿瘤学治疗公司 | 三环衍生化合物、其制备方法、和含有其的药物组合物 |
| WO2018011017A1 (de) | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
-
2016
- 2016-06-06 CN CN201680046695.4A patent/CN107949562B/zh active Active
- 2016-06-06 CU CUP2017000158A patent/CU20170158A7/es unknown
- 2016-06-06 MX MX2017016055A patent/MX370113B/es active IP Right Grant
- 2016-06-06 AU AU2016274433A patent/AU2016274433B2/en not_active Expired - Fee Related
- 2016-06-06 EP EP16727193.1A patent/EP3307741B1/de active Active
- 2016-06-06 CR CR20170566A patent/CR20170566A/es unknown
- 2016-06-06 BR BR112017026561-3A patent/BR112017026561A2/pt not_active Application Discontinuation
- 2016-06-06 SG SG11201710164QA patent/SG11201710164QA/en unknown
- 2016-06-06 KR KR1020187000247A patent/KR20180016485A/ko not_active Application Discontinuation
- 2016-06-06 CA CA2988468A patent/CA2988468A1/en active Pending
- 2016-06-06 US US15/735,138 patent/US10435403B2/en active Active
- 2016-06-06 UY UY0001036714A patent/UY36714A/es not_active Application Discontinuation
- 2016-06-06 EP EP19216135.4A patent/EP3692991A1/de not_active Withdrawn
- 2016-06-06 TN TNP/2017/000498A patent/TN2017000498A1/en unknown
- 2016-06-06 WO PCT/EP2016/062737 patent/WO2016198342A1/de active Application Filing
- 2016-06-06 EA EA201890002A patent/EA035465B1/ru not_active IP Right Cessation
- 2016-06-06 JP JP2017564437A patent/JP6908536B2/ja active Active
- 2016-06-06 PE PE2017002542A patent/PE20180252A1/es unknown
- 2016-06-07 TW TW105117915A patent/TW201716405A/zh unknown
-
2017
- 2017-12-05 IL IL256119A patent/IL256119A/en unknown
- 2017-12-06 CL CL2017003124A patent/CL2017003124A1/es unknown
- 2017-12-07 CO CONC2017/0012622A patent/CO2017012622A2/es unknown
- 2017-12-07 DO DO2017000288A patent/DOP2017000288A/es unknown
- 2017-12-07 PH PH12017502224A patent/PH12017502224A1/en unknown
- 2017-12-07 NI NI201700154A patent/NI201700154A/es unknown
- 2017-12-08 EC ECIEPI201781322A patent/ECSP17081322A/es unknown
-
2018
- 2018-01-08 ZA ZA2018/00125A patent/ZA201800125B/en unknown
- 2018-10-19 HK HK18113424.9A patent/HK1254348A1/zh unknown
-
2019
- 2019-08-13 US US16/539,652 patent/US20190367516A1/en not_active Abandoned
-
2020
- 2020-01-13 IL IL272017A patent/IL272017A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201700154A (es) | Moduladores alostéricos positivos de | |
| CL2018003142A1 (es) | Moduladores de la vía de estrés integrada | |
| CO2019013707A2 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| BR112018073384A2 (pt) | polinucleotídeos moduladores | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CL2018003597A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
| DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| BR112017008198A2 (pt) | pró-fármacos de carbidopa e l-dopa e métodos de uso | |
| CL2018002335A1 (es) | Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1 | |
| CU20140082A7 (es) | Pirimidinas y triazinas fusionadas sustituidas y sus uso | |
| EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
| EA201790785A1 (ru) | Производные тетрагидроизохинолина | |
| EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
| BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
| DOP2017000087A (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos | |
| BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| UY35344A (es) | Oestra-1,3,5(10),16-tetraeno-3-carboxamidas | |
| CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
| DOP2019000060A (es) | 1arilnaftiridin3carboxamidas 7sustituidas y su uso | |
| UY35746A (es) | Derivados de fenilalanina sustituidos | |
| BR112016017776A2 (pt) | Formas sólidas de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, composições das mesmas e métodos para seu uso |